
Neurologist

No OPD information available
Neurofibromatosis
Neurofibromatosis Type 1 (NF1)
Memory Loss
Schwannomatosis
Attention Deficit Hyperactivity Disorder (ADHD)
Autism Spectrum Disorder
Epilepsy
Genetic Epilepsy with Febrile Seizures Plus (GEFS+)
Kidney Transplant
Partial Familial Epilepsy
Transposition of the Great Arteries
Belinda L. Barton is a female healthcare provider who helps people with various medical conditions. She specializes in treating Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Memory Loss, Schwannomatosis, Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder, Epilepsy, Genetic Epilepsy with Febrile Seizures Plus (GEFS+), Kidney Transplant, Partial Familial Epilepsy, and Transposition of the Great Arteries.
Belinda uses special skills and treatments to care for her patients. She talks to them in a way that makes them feel comfortable and safe. Patients trust her because she listens to their concerns and works with them to find the best solutions for their health.
Belinda stays updated with the latest medical knowledge and research to provide the best care for her patients. She learns new things so she can help people better. Belinda also works well with other medical professionals. She shares information and collaborates with colleagues to give patients the best care possible.
Belinda's work has positively impacted many patients' lives. She has helped people with different health issues and improved their quality of life. Belinda has also contributed to medical research through her publications, such as "Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials." She has been involved in clinical trials like "The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults."
Belinda L. Barton is a caring and knowledgeable healthcare provider who works hard to help her patients and make a positive difference in their lives.
Enrollment Status: Completed
Published: March 09, 2023
Intervention Type:
Study Drug:
Study Phase:
